Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis
International Journal of Molecular Sciences · 19.11.2023 · 24 (22) · 16502
DOI: 10.3390/ijms242216502 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.11.2023. Verfasst von Roman Maslennikov und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, 119048 Moscow, Russia. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Liver Diseases. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cirrhosis is the end result of liver fibrosis in chronic liver diseases. Studying the mechanisms of its development and developing measures to slow down and regress it based on this knowledge seem to be important tasks for medicine. Currently, disorders of the gut–liver axis have great importance in the pathogenesis of cirrhosis. However, gut dysbiosis, which manifests as increased proportions in the gut microbiota of Bacilli and Proteobacteria that are capable of bacterial translocation and a decreased proportion of Clostridia that strengthen the intestinal barrier, occurs even at the pre-cirrhotic stage of chronic liver disease. This leads to the development of bacterial translocation, a process by which those microbes enter the blood of the portal vein and then the liver tissue, where they activate Kupffer cells through Toll-like receptor 4. In response, the Kupffer cells produce profibrogenic cytokines, which activate hepatic stellate cells, stimulating their transformation into myofibroblasts that produce collagen and other elements of the extracellular matrix. Blocking bacterial translocation with antibiotics, probiotics, synbiotics, and other methods could slow down the progression of liver fibrosis. This was shown in a number of animal models but requires further verification in long-term randomized controlled trials with humans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Gastroenterology and Hepatology, Sechenov University, 119048 Moscow, Russia.
- The Interregional Public Organization "Scientific Community for the Promotion of the Clinical Study of the Human Microbiome", 119048 Moscow, Russia.
ORCID-Profile: Roman Maslennikov, Anastasia Kurbatova, Maria Nadinskaia, Anna Karchevskaya
Zitieren
APA
Maslennikov, R., Poluektova, E., Zolnikova, O., Sedova, A., Kurbatova, A., Shulpekova, Y., Dzhakhaya, N., Kardasheva, S., Nadinskaia, M., Bueverova, E., Nechaev, V., Karchevskaya, A., & Ivashkin, V. (2023). Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis. International Journal of Molecular Sciences, 24(22), 16502. https://doi.org/10.3390/ijms242216502
Vancouver
Maslennikov R, Poluektova E, Zolnikova O, Sedova A, Kurbatova A, Shulpekova Y, et al. Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis. International Journal of Molecular Sciences. 2023;24(22):16502. doi:10.3390/ijms242216502
BibTeX
@article{Maslennikov2023,
author = {Maslennikov, Roman and Poluektova, Elena and Zolnikova, Oxana and Sedova, Alla and Kurbatova, Anastasia and Shulpekova, Yulia and Dzhakhaya, Natyia and Kardasheva, Svetlana and Nadinskaia, Maria and Bueverova, Elena and Nechaev, Vladimir and Karchevskaya, Anna and Ivashkin, Vladimir},
title = {Gut Microbiota and Bacterial Translocation in the Pathogenesis of Liver Fibrosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {22},
pages = {16502},
doi = {10.3390/ijms242216502}
}
EUVIMED